A Case of EGFR Gene Mutation-positive Early Lung Adenocarcinoma That Recurred 12 Years Postoperatively with Meningeal Carcinomatosis Alone

AbstractObjectiveTo discuss the application of ARMS method to detect EGFR gene mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis.Methods5 cases of lung adenocarcinoma were identified with meningeal metastasis that were cleared EGFR gene mutation by gene sequencing method. From each patient 5ml cerebrospinal fluid was obtained by lumbar puncture. ARMS method was used to detect EGFR mutations in cerebrospinal fluid.Results5 samples of cerebrospinal fluid were successfully detected by ARMS method, 3 samples found that EGFR gene mutations, the mutations in line with direct sequencing method.ConclusionARMS method can be used to detect EGFR gene mutations of cerebrospinal fluid samples in lung adenocarcinoma with meningeal metastasis. But cerebrospinal fluid specimens from histological specimens, blood samples need to be confirmed by further comparative study whether there is advantage.

Download Full-text

LATE-BREAKING ABSTRACT: Treatment efficacy of afatinib vs gefitinib in lung adenocarcinoma with EGFR gene mutation

10.1183/13993003.congress-2016.pa2880 ◽

2016 ◽

Author(s):

Marisol Arroyo Hernandez ◽

Alexander J. Alatorre ◽

Julio C. Garibay ◽

José F. Escobar ◽

Jerónimo Rodríguez

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Treatment Efficacy ◽

Egfr Gene ◽

Egfr Gene Mutation

Download Full-text

The value of Fn14, CD44v, and EGFR expression in lung adenocarcinoma patients with and without activating EGFR gene mutation.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e20514 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e20514-e20514

Author(s):

Maciej Bryl ◽

Katarzyna Bednarek-Rajewska ◽

Przemysław Zalewski ◽

Małgorzata Janicka-Jedyńska ◽

Rodryg Ramlau ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Prognostic Value ◽

Neoplastic Disease ◽

Study Group ◽

Secondary Resistance ◽

Egfr Gene ◽

Egfr Expression ◽

Nsclc Patients ◽

Egfr Gene Mutation

e20514 Background: Lung cancer is considered the most common cause of death in the world. The prognosis for patients is poor and depends on the clinical stage and the histological type of cancer. There is a need to identify and develop new therapeutic targets that could improve the prognosis of NSCLC patients and may be responsible for development of resistance to TKI therapy. Increased expression of Fn14 or CD44v and EGFR was observed in many tumors and also correlated with the overall survival of NSCLC patients Methods: We analyzed the clinical data and the immunohistochemical expression of Fn14, CD44v and EGFR in tumor tissues from 61 patients with NSCLC divided in two groups according to the presence of activating EGFR gene mutation. The aim of the study was to evaluate the correlation between the expression of the studied molecules and the neoplastic disease course of NSCLC patients. Results: Increased expression of Fn14 was observed in study group (B) compared to expression of this molecule in the control group (K). There were no differences in the intensity of the reaction with anti CD44v and EGFR antibodies in both groups. OS was significantly longer in the study group. Histological grade of tumor correlated with the intensity of CD44v expression in both groups. There was no correlation between the OS and Fn14 expression in any group. Negative correlation was noted between the expression of CD44v and the OS in the study group and between EGFR expression and the OS in both groups. Conclusions: Our observations suggest that the expression of CD44v and EGFR may be useful clinical markers of prognostic value in lung adenocarcinoma patients regardless of the presence of activating mutation in EGFR gene. Simultaneous assessment of Cd44v and EGFR expression may grant a greater prognostic value than the assessment of each receptor separately. Increased expression of Fn14 receptor in patients with EGFR gene mutation may become a new target in therapy allowing to eliminate the problem of secondary resistance to treatment with TKI’s

Download Full-text

P3.16-013 Prognostic Effect of EGFR Gene Mutation for Recurrence in Completely Resected Lung Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1819 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2348

Author(s):

I.K. Park ◽

K. Hyun ◽

S. Park ◽

C.H. Kang ◽

Y. Kim

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Egfr Gene ◽

Prognostic Effect ◽

Egfr Gene Mutation

Download Full-text

P3.02b-107 Efficacy of Afatinib and Gefitinib in Lung Adenocarcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.11.1775 ◽

2017 ◽

Vol 12 (1) ◽

pp. S1258

Author(s):

Marisol Arroyo Hernandez ◽

Jerónimo Rodríguez Cid ◽

Jorge Alatorre Alexander ◽

José Escobar-Penagos ◽

Julio Garibay-Diaz

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Line Treatment ◽

Egfr Gene ◽

Egfr Gene Mutation

Download Full-text

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

World Journal of Surgical Oncology ◽

10.1186/s12957-017-1103-x ◽

2017 ◽

Vol 15 (1) ◽

Cited By ~ 3

Author(s):

Yunqiang Nie ◽

Wei Gao ◽

Na Li ◽

Wenjun Chen ◽

Hui Wang ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Egfr Gene ◽

Local Metastasis ◽

Egfr Gene Mutation

Download Full-text

Miliary pattern on chest imaging as a presentation of EGFR-negative primary lung adenocarcinoma

BMJ Case Reports ◽

10.1136/bcr-2018-228534 ◽

2019 ◽

Vol 12 (5) ◽

pp. e228534 ◽

Cited By ~ 1

Author(s):

Seth A Hoffman ◽

Scott Manski ◽

Janaki Deepak

Keyword(s):

Lung Adenocarcinoma ◽

Gene Mutation ◽

Lung Metastases ◽

Case Reports ◽

Growth Factor Receptor ◽

Smoking History ◽

Egfr Gene ◽

Primary Lung Adenocarcinoma ◽

Bilateral Lung ◽

Egfr Gene Mutation

A 64-year-old African American man, with a history of prostate adenocarcinoma treated in 2009 and a greater than 50-pack-year tobacco smoking history, presented with 2–3 weeks of non-productive cough, frontal headache and generalised myalgias and arthralgias. CT was positive for diffuse, miliary opacities in bilateral lung fields. He was diagnosed with stage four lung adenocarcinoma, negative for epidermal growth factor receptor (EGFR) gene mutation. The patient was unable to tolerate therapy and passed away approximately 4 months after his diagnosis. Previous case reports and research have suggested an association between EGFR gene mutation and miliary patterned lung metastases in non-small cell lung cancer. This case suggests that the mechanism by which miliary patterned metastases occur is more complex than purely mutation of the EGFR gene. Further study may elucidate novel molecular targets for treatment, especially in patients with rapidly progressive disease such as the patient we describe.

Download Full-text